Ultime notizie per Charles River (NYSE:CRL) Azioni

Charles River

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Charles River Laboratories International, Inc. Common Stock

Charles River Laboratories International Inc

Cresco Labs Inc

CARDINAL ENERGY LTD ORD by Cardinal Energy Ltd.

Cardinal Energy Ltd

CIRCUIT RESEARCH LABS INC by Circuit Research Labs, Inc.

CENTRAL PRKNG F/T 5.25PFD by Central Parking Finance Trust

Central Parking Financial Trust

Cerillion PLC

Wall Street pared early morning gains by midday Monday, as investor caution returned despite a temporary easing in U.S.-China trade tensions. While the initial market reaction was positive, especially in tech, enthusiasm faded as <a href="https://www.benzinga.com/markets">the trading session progressed.</a>
Over the weekend, the White House announced a provisional exemption for smartphones and semiconductors from China&#8217;s proposed 145% trade tariff. These items will instead face a 20% levy—linked to fentanyl-related enforcement—until sector-specific duties are finalized.
The development triggered a strong premarket rally in technology stocks. Yet, those gains were sharply trimmed by midday amid broader geopolitical and policy concerns.
During a White House meeting with El Salvador President Nayib Bukele, President Donald Trump said he plans to impose tariffs on pharmaceutical imports to boost domestic manufacturing. 
He reiterated a hardline stance on Iran, warning of severe consequences if Tehran develops nuclear weapons, but also suggested &#8220;flexibility&#8221; in tariff negotiations, emphasizing a desire not to harm U.S. businesses.
Defensive and domestic-oriented sectors such as real estate, utilities, and consumer staples outperformed broader markets. In contrast, consumer discretionary was the only sector trading in negative territory.
Treasury yields dropped significantly, reflecting increased demand for U.S. government debt and easing fears of foreign liquidation. The 2-year yield fell 10 basis points to 3.87%, while 10-year benchmark yield dropped 7 basis points to 4.42%.
Gold pulled back 1% to $3,200 per ounce, pausing after a three-session rally. Crude oil fell 0.8% to $61 per barrel, while natural gas slid 2.9% to $3.39 per MMBtu, eyeing its lowest level since last Wednesday.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was little changed at $84,000, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) gained 2.1% to $1,630.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,326.49</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,377.08</td>
<td>0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,695.41</td>
<td>0.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,856.16</td>
<td colspan="2">-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.5% up to $537.23.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.4% to $403.81.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.4% higher to $454.38.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.1% higher to 184.74.</li>
<li>The&nbsp;Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 1.9%; the&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 0.5%.</li>
</ul>
In company news, Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reported stronger-than-expected earnings during the first quarter, and shares rose 1.9%.
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company </th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>)</td>
<td>6.91%</td>
</tr>
<tr>
<td>Charles River Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)</td>
<td>5.98%</td>
</tr>
<tr>
<td>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)</td>
<td>4.69%</td>
</tr>
<tr>
<td>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)</td>
<td>4.64%</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>4.15%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)</td>
<td>-3.80%</td>
</tr>
<tr>
<td>DaVita Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>)</td>
<td>-3.61%</td>
</tr>
<tr>
<td>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-3.04%</td>
</tr>
<tr>
<td>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>)</td>
<td>-2.39%</td>
</tr>
<tr>
<td>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>-2.36%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/44794083/7-chipmaker-stocks-set-to-gain-as-trump-delays-tariff-blow-on-key-china-tech-imports-bank-of-america">7 Chipmaker Stocks Set To Gain As Trump Delays Tariff Blow On Key China Tech Imports: Bank Of America</a></li>
</ul>
Photo: Shutterstock

Equities

Government

Large Cap

Macro Economic Events

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

$ETH

AMZN

SPDR Dow Jones Industrial Average ETF Trust

ENPH

FSLR

PLTR

SNDK

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Pulls Back After Early Gains As Tariff Uncertainties Persist: What's Driving Markets Monday?

The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) and Ginkgo Bioworks Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) rallying last week. 
What Happened: On Thursday, the new FDA commissioner, Martin Makary, announced a major reform to its drug evaluation standards. As per <a href="https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs">the</a> agency&#8217;s press release, mandatory animal testing is no longer required for monoclonal antibody therapies and other drugs, and it would instead be replaced with &#8220;more effective, human relevant methods.&#8221;
The agency lays out several approaches to replace animal testing, such as AI-based computational models of toxicity, cell lines, and organoid toxicity testing in a laboratory setting. 
See More: <a href="https://benzinga.com/general/biotech/25/04/44751934/fda-grants-complete-approval-to-bayers-drug-for-certain-type-cancer-with-mutation">FDA Grants Complete Approval To Bayer&#8217;s Drug For Certain Type Cancer With Mutation</a>
Calling it a &#8220;win-win for public health and ethics,&#8221; commissioner Makary adds that drug manufacturers have performed animal testing of drugs longer than was necessary, especially those &#8220;drugs that have data in broad human use internationally.&#8221;
The move sent Nvidia Corp.-backed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Recursion Pharmaceuticals, along with Ginkgo Bioworks, Absci Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) and Schrodinger Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>), all techBio or AI-enabled biotech companies, rallying 27.72%, 11.23%, 23%, and 27.42%, respectively, following the announcement. 
On the flip side, however, companies operating in the preclinical laboratory services industry, such as Charles River Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) and Inotiv Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) witnessed a steep pullback of nearly 28%, and 44%, respectively, being major legacy players in the contract research organization (CRO) space.
Why It Matters: Leading biotech analysts have, however, expressed mixed views on the FDA&#8217;s announcement, with Leerink Partners analysts referring to it as &#8220;more public relations than a change in policy,&#8221; adding that they expect minimal near-term impact on preclinical testing, as <a href="https://www.biospace.com/fda/fda-to-replace-some-animal-testing-with-ai-human-organoid-lab-models">reported</a> by BioSpace.
Analyst Rick Weissenstein of TD Cowen had a rather optimistic take on the announcement, <a href="https://www.axios.com/2025/04/10/fda-animal-testing-drug-trials">stating</a> to Axios that the initiative &#8220;combines deregulatory themes and cutting-edge technology,&#8221; in service of a broadly popular goal of reducing animal testing.
Weissenstein further adds that the FDA&#8217;s plans could help accelerate drug development with the use of AI and by leveraging computational models, resulting in lower costs and improved safety. 
<figure class="wp-block-image aligncenter size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="148" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM-1024x148.png" alt="" class="wp-image-869611" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM-1024x148.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM-300x44.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM-768x111.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM-1536x223.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM.png 1600w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Despite its rally over the past week, shares of Recursion Pharmaceuticals don&#8217;t score too well on Benzinga&#8217;s Edge Stock Rankings, but what about Ginkgo Bioworks and Schrodinger? Sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge Stock Rankings</a> today for more such insights.
Read More: <a href="https://benzinga.com/insights/options/25/03/44203832/this-is-what-whales-are-betting-on-recursion-pharmaceuticals">This Is What Whales Are Betting On Recursion Pharmaceuticals</a>
Photo courtesy: Shutterstock

Biotech

News

Health Care

Markets

ABSI

NOTV

NVDA

RXRX

SDGR

Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing

Wall Street regained momentum, reversing early-session losses and pushing major indexes into positive territory by midday trading in New York, as investors welcomed upbeat bank earnings and cooler-than-expected inflation data, while largely shrugging off trade war concerns after China raised tariffs on <a href="https://www.benzinga.com/markets/25/04/44756353/xi-jinping-says-there-are-no-winners-in-tariff-war-as-china-slaps-125-tariffs-on-us-goods-urges-trump-to-immediately-correct-wrongdoings">U.S. goods to 125%.</a>
Producer prices cooled to 2.7% year-over-year in March, well below the 3.3% consensus, while the monthly figure declined by 0.4% — the steepest drop since 2023. 
A day earlier, consumer prices also eased more than expected. However, both inflation reports predate the implementation of new trade tariffs. The University of Michigan's latest consumer sentiment index fell sharply to 50.4, its lowest since June 2022 and below expectations. 
Meanwhile, inflation expectations surged: short-term projections hit their highest since 1990, and long-term views reached levels last seen in 1981, underscoring growing concerns over persistent price pressures. In the bond market, the 30-year Treasury yield retreated to 4.90% after briefly touching 4.99% during intraday trading. 
The dollar pared some losses, though it remained near its lowest level since April 2022, based on a trade-weighted index. 
JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) topped first-quarter earnings estimates and issued upbeat guidance, lifting its shares nearly 3% and outpacing peers. 
Gold prices extended their rally, jumping 1.9% to a record $3,230 per ounce — poised for their strongest weekly gain since March 2020. The surge in bullion and silver — with the latter rising over 3% on Friday — sparked strong gains in mining stocks. 
The VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>) soared 5.5% on Friday and nearly 20% for the week, heading for its highest level since December 2012. 
Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), the world's largest gold miner, jumped 9% on the day and 25% on the week, marking its best weekly performance since 1998.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,623.30</td>
<td>1.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,333.87</td>
<td>1.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,056.72</td>
<td>1.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,838.01</td>
<td>0.4%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rallied 1.3% to $531.82.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 1.2% to $400.45.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;soared 1.5% to $452.67.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.4% to $182.36.</li>
<li>The&nbsp;Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) outperformed, up 2.3%; the&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 0.1%.</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Performers On Friday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company Name </th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newmont Corp. </td>
<td>+8.73%</td>
</tr>
<tr>
<td>Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)</td>
<td>+7.55%</td>
</tr>
<tr>
<td>Huntington Ingalls Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>)</td>
<td>+6.87%</td>
</tr>
<tr>
<td>Fastenal Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>)</td>
<td>+6.83%</td>
</tr>
<tr>
<td>The Mosaic Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>)</td>
<td>+6.12%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers On Friday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company Name </th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles River Laboratories International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)</td>
<td>-6.25%</td>
</tr>
<tr>
<td>Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>)</td>
<td>-6.19%</td>
</tr>
<tr>
<td>SanDisk Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>)</td>
<td>-3.93%</td>
</tr>
<tr>
<td>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>)</td>
<td>-3.30%</td>
</tr>
<tr>
<td>Warner Bros. Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>-3.23%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44762609/producer-inflation-sharply-drops-yet-treasury-yields-rise-heres-why-a-fed-rate-cut-in-may-could-be-back-on-the-table">Inflation Cools, Yields Continue To Climb: Why Markets Aren&#8217;t Ruling Out A May Rate Cut</a></li>
</ul>
Photo: emin kuliyev/Shutterstock

Bonds

Commodities

Treasuries

FAST

Market Vectors ETF Trust Market Vectors Gold Miners

MPWR

NCLH

Wall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday?

The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">traditional animal testing</a>.
The agency aims to adopt human-relevant and technologically advanced testing methods to improve safety evaluations, reduce research costs and accelerate drug development timelines.
The FDA&#8217;s new approach, <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs" rel="noreferrer noopener">outlined</a> in a roadmap released on Thursday, encourages drug developers to integrate New Approach Methodologies (NAMs), including AI-driven simulations and laboratory-based human models.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44761003/sony-nintendo-hike-console-prices-as-us-tariffs-bite-microsoft-may-dodge-the-hit" rel="noreferrer noopener">Sony, Nintendo Hike Console Prices As US Tariffs Bite, Microsoft May Dodge The Hit</a>
These alternatives are expected to provide more accurate predictions of human responses and toxicities, which can be difficult to detect through animal testing alone.
One key strategy promoted in the roadmap is the use of advanced computer modeling.
AI-based simulations can mimic how monoclonal antibodies travel through the human body and predict potential side effects based on the drug&#8217;s structure. The FDA believes this could significantly reduce the reliance on animals in preclinical studies.
In addition, the agency is supporting the use of lab-grown human organoids and organ-on-a-chip technologies.
These systems replicate the function of human organs like the liver and heart, offering a more precise picture of how a drug might behave in the human body.
Such human-based models have the potential to detect adverse effects that may not surface in animal studies.
To incentivize the adoption of these methods, the FDA plans to update regulatory guidelines and offer streamlined reviews for applications supported by NAMs data.
This could shorten development timelines and lower the cost of bringing monoclonal antibody therapies to market.
The agency will also begin using real-world safety data from countries with comparable regulatory standards, particularly for drugs already tested in humans abroad.
This marks another step toward reducing redundant animal testing while maintaining rigorous safety standards.
The FDA is working to validate and expand these alternative methods in collaboration with federal agencies such as the National Institutes of Health and the Department of Veterans Affairs.
A public workshop is scheduled later this year to gather feedback from stakeholders on the roadmap&#8217;s rollout.
Over the next year, the FDA will pilot a program allowing select developers to rely primarily on non-animal testing methods for monoclonal antibody development.
William Blair writes that even though these changes will be rolled out gradually over time, drug developers will still want to do at least some animal testing. This may be a major overhang for Charles River Laboratories International, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), which generates roughly 20% of its revenue from testing drugs in non-human primates. The stock plunged over 20% on Thursday.
Analyst Max Smock adds that the move can be potentially favorable to Certara Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) and Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), both of which have preclinical models that can be used in place of or in conjunction with animal-based testing.
CRL, CERT, SLP Price Actions: Charles River stock is down 1.84% at $96.68, Certara stock is up 13.5% at $11.96 and Simulations Plus stock is up 22.80% at $31.61 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertainties" target="_blank" rel="noreferrer noopener">Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Analyst Ratings

Movers

Trading Ideas

General

CERT

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

WIIM

Charles River Laboratories shares are trading higher. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.

<a href="https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs#:~:text=Today%2C%20the%20U.S.%20Food%20and,effective%2C%20human%2Drelevant%20methods" title="https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs#:~:text=Today%2C%20the%20U.S.%20Food%20and,effective%2C%20human%2Drelevant%20methods">https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs#:~:text=Today%2C%20the%20U.S.%20Food%20and,effective%2C%20human%2Drelevant%20methods</a>.

'FDA Announces Plan to Phase Out Animal Testing Requirement For Monoclonal Antibodies And Other Drugs' - FDA

Barclays analyst Luke Sergott maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Equal-Weight and lowers the price target from $160 to $145.

Price Target

Barclays Maintains Equal-Weight on Charles River, Lowers Price Target to $145

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Charles River, revealing an average target of $172.55, a high estimate of $190.00, and a low estimate of $155.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 11.64%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744221647_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Charles River by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Lowers &#x7C;Neutral &#x7C; $155.00&#x7C;$175.00 &#x7C; 
&#x7C;Matthew Sykes &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $170.00&#x7C;$190.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $175.00&#x7C;$155.00 &#x7C; 
&#x7C;Casey Woodring &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $165.00&#x7C;$175.00 &#x7C; 
&#x7C;Eric Coldwell &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $173.00&#x7C;$177.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $160.00&#x7C;$166.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $166.00&#x7C;$205.00 &#x7C; 
&#x7C;Ricky Goldwasser &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $184.00&#x7C;$220.00 &#x7C; 
&#x7C;Casey Woodring &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $175.00&#x7C;$215.00 &#x7C; 
&#x7C;Matthew Sykes &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $190.00&#x7C;$220.00 &#x7C; 
&#x7C;Dan Leonard &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $185.00&#x7C;$250.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Charles River. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Charles River's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Charles River's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Charles River analyst ratings.</a>
<h2>All You Need to Know About Charles River</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>Charles River's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Charles River's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -1.08%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Charles River's net margin excels beyond industry benchmarks, reaching -21.52%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -5.96%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Charles River's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.78%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Charles River's debt-to-equity ratio is below the industry average at 0.79, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Charles River Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

Mizuho analyst Ann Hynes maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $175 to $155.

Mizuho Maintains Neutral on Charles River, Lowers Price Target to $155

Throughout the last three months, 10 analysts have evaluated Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $174.3, a high estimate of $190.00, and a low estimate of $160.00. Observing a downward trend, the current average is 11.66% lower than the prior average price target of $197.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1742580053_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Charles River by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$173.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$160.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$184.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Charles River. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Charles River's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Charles River's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Charles River analyst ratings.</a>
<h2>All You Need to Know About Charles River</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>Financial Insights: Charles River</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Charles River's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -1.08%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -21.52%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -5.96%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Charles River's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.78%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.79.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Charles River: Insights From 10 Analyst Reviews

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Matthew Sykes downgraded the rating for Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Buy to Neutral and lowered the price target from $190 to $170. Charles River shares closed at $165.35 on Thursday. <a href="https://www.benzinga.com/quote/CRL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Matthew Caufield downgraded OptiNose, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) from Buy to Neutral and lowered the price target from $18 to $9. OptiNose shares closed at $9.15 on Thursday. <a href="https://www.benzinga.com/quote/OPTN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Rick Paterson downgraded the rating for FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from Hold to Sell and lowered the price target from $283 to $221. FedEx shares closed at $246.21 on Thursday. <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Brian Drab downgraded the rating for Valmont Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) from Outperform to Market Perform. Valmont Industries shares closed at $326.58 on Thursday. <a href="https://www.benzinga.com/quote/VMI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Jason Haas downgraded FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) from Equal-Weight to Underweight and slashed the price target from $450 to $402. FactSet Research shares closed at $430.93 on Thursday. &nbsp;<a href="https://www.benzinga.com/quote/FDS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying FDX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/21091713/image-198-1024x579.png" alt="" class="wp-image-835942" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/21091713/image-198-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/21091713/image-198-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/21091713/image-198-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/21091713/image-198.png 1091w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44414749/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-march">Top 2 Defensive Stocks That May Keep You Up At Night In March</a></li>
</ul>
Photo: Shutterstock

Downgrades

OPTN

This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Goldman Sachs analyst Matthew Sykes downgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Buy to Neutral and lowers the price target from $190 to $170.

Goldman Sachs Downgrades Charles River to Neutral, Lowers Price Target to $170

Citigroup analyst Patrick Donnelly upgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Sell to Neutral and raises the price target from $155 to $175.

Upgrades

Citigroup Upgrades Charles River to Neutral, Raises Price Target to $175

JP Morgan analyst Casey Woodring maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $175 to $165.

JP Morgan Maintains Neutral on Charles River, Lowers Price Target to $165

Baird analyst Eric Coldwell maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $177 to $173.

Baird Maintains Neutral on Charles River, Lowers Price Target to $173

Barclays analyst Luke Sergott maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Equal-Weight and lowers the price target from $166 to $160.

Barclays Maintains Equal-Weight on Charles River, Lowers Price Target to $160

On Wednesday, Charles River Laboratories International Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $983.63 million</a>.
In the fourth quarter of 2024, the operating margin decreased to (16.7)% from 13.1% a year ago, including a non-cash goodwill impairment of&nbsp;$215.0 million&nbsp;in the fourth quarter of 2024 related to the Biologics Solutions reporting unit, which includes the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43808708/charles-river-laboratories-announces-fourth-quarter-and-full-year-2024-results-and-provides-2025-g" rel="noreferrer noopener">Biologics Testing and CDMO businesses</a>.
Adjusted operating margin increased to 19.9% from 19.1%, due primarily to higher revenue and operating income in the Manufacturing segment and lower unallocated corporate costs.
The company reported adjusted EPS of $2.66, down from $2.46 a year ago, surpassing the consensus estimate of $2.53.
James C. Foster, Chair, President and Chief Executive Officer, said, "Throughout 2024, we have launched initiatives to generate more revenue, aggressively reduce costs, and further strengthen our business. As we move into 2025, we see many of our global biopharmaceutical clients continuing to move forward with their restructuring and pipeline reprioritization activities, which are expected to constrain early-stage spending by many of these clients again in 2025.&#8221;
&#8220;We believe these trends are stabilizing, and therefore, our view of the global biopharmaceutical demand environment remains unchanged. In addition, small and mid-sized biotechnology clients continued to benefit from a more favorable funding environment in 2024, and we expect biotechnology demand trends will be stable to slightly improved this year."
Revenue for the Discovery and Safety Assessment segment was $603.3 million, down 3.6%. Organic revenue decreased by 3.5%, driven primarily by lower sales volume, as well as slightly lower pricing.
Research Models and Services&nbsp;sales increased 4.3% to $204.3 million.
The Noveprim acquisition in&nbsp;November 2023 contributed 4.8% to fourth-quarter RMS reported revenue, and the impact of foreign currency translation reduced revenue by 0.1%. Organic revenue decreased by 0.4%, due primarily to lower revenue for research models services and the Cell Solutions business, as well as lower sales for non-human primates in&nbsp;China.
Guidance:&nbsp;Charles River Laboratories expects 2025 revenue to decline between 7% and 4.5% on a reported basis and 5.5% and 3.5% organically.
Charles River sees the fiscal year 2025 adjusted EPS of $9.10-$9.60 versus a consensus of $9.60.
William Blair analyst Max Smock writes that the initial release reinforced the view that Charles River remains the premier preclinical CRO, and the analyst is confident in its best-in-class offerings.
&#8220;There is too much working against the company in the near term to make the stock interesting,&#8221; analyst writes. William Blair <a target="_blank" href="https://www.benzinga.com/quote/CRL/analyst-ratings" rel="noreferrer noopener">reiterates the Market Perform rating</a>.
Price Action: At last check on Wednesday, CRL stock closed up 6.87% to $165.01.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43816882/manchester-uniteds-q2-revenue-drops-12-but-ebitda-forecasts-brighten-fiscal-2025" target="_blank" rel="noreferrer noopener">Manchester United&#8217;s Q2 Revenue Drops 12%, But EBITDA Forecasts Brighten Fiscal 2025</a></li>
</ul>

Earnings

Guidance

Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance

Charles River Sees FY25 Adjusted EPS Of $9.10-$9.60 Vs. $9.60 Estimate

Charles River Plans To Repurchase Approximately $350M In Common Stock In 2025

Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $2.53 by 5.14 percent. This is a 8.13 percent increase over earnings of $2.46 per share from the same period last year. The company reported quarterly sales of $1.003 billion which beat the analyst consensus estimate of $983.627 million by 1.97 percent. This is a 1.03 percent decrease over sales of $1.013 billion the same period last year.

Earnings Beats

Charles River Q4 2024 Adj. EPS $2.66 Beats $2.53 Estimate, Sales $1.003B Beat $983.627M Estimate

Press Releases

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call

Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

Charles River Announces Agreement with Singapore General Hospital

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

FHTX

MRNA

SANA

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Charles River

Notizie

Ultime notizie per Charles River (NYSE:CRL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO